Who’s Who with ReNerve: Building the future of bioengineered nerve healing

Host Tylah Tully unpacks ReNerve (ASX:RNV) in this latest episode of Who’s Who on the ASX, a cutting-edge biotech developing “ready-to-use” products for nerve repair and regeneration.

From its FDA-approved NervAlign nerve cuff to its expanding suite of bioengineered tissue products under a partnership with Berkeley Biologics, ReNerve is reshaping how damaged nerves and soft tissues are treated.

Listed in late 2024, the company is already expanding across Asia, the Middle East and the Americas, tapping into a $6.2 billion global market growing at more than 17% annually.

Backed by an experienced leadership team, ReNerve is positioning itself as a global leader in the booming nerve repair biomaterials sector.

Watch the video for more.

This video was developed in collaboration with ReNerve, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.